Research Progress in the Treatment of Pain from Metastatic Bone Cancer

doi:10.12114/j.issn.1007-9572.2019.00.740

Abstract

Abstract: Bone metastatic cancer is a common complication of tumor patients，and its incidence accounts for about 15%-20% of systemic metastatic cancer following the incidence of lung and liver metastatic cancer.Malignant tumors prone to bone metastasis include lung cancer，breast cancer，prostate cancer，etc.Pain is the most common clinical symptom of bone metastasis，and its early symptoms are insidious.As the disease progresses，the symptoms become worsen，and the acute pain is in the late stage，which poses a serious threat to the quality of life of cancer patients.Therefore，this paper systematically introduces the current situation of the treatment of pain from bone metastatic cancer through western and traditional Chinese medicine by reviewing domestic and foreign literatures，so as to provide suggestions and references for the clinical treatment of pain from bone metastatic cancer.

Key words: Bone neoplasms, Bone metastasis cancer, Pain, Therapy, Review

摘要： 骨转移癌是肿瘤患者常见并发症，其发病率占全身转移癌的15%~20%，仅次于肺及肝转移癌的发病率。易发生骨转移癌的恶性肿瘤包括肺癌、乳腺癌、前列腺癌等，而疼痛是骨转移癌最常见的临床症状，早期症状隐匿，随着病情进展，症状逐渐加重，晚期疼痛剧烈，给肿瘤患者的生存质量带来严重威胁。因此，本研究通过检索国内外文献，系统介绍了西医及中医治疗骨转移癌疼痛的现状，以期为骨转移癌疼痛的临床治疗提供建议和参考。

关键词: 骨肿瘤, 骨转移癌, 疼痛, 治疗, 综述

WANG Xiao,CHEN Li,LIU Guangjie, et al. Research Progress in the Treatment of Pain from Metastatic Bone Cancer　[J]. Chinese General Practice, 2020, 23(12): 1571-1575. DOI: 10.12114/j.issn.1007-9572.2019.00.740.
王骁,陈丽,刘广杰等. 骨转移癌疼痛的治疗进展[J]. 中国全科医学, 2020, 23(12): 1571-1575. DOI: 10.12114/j.issn.1007-9572.2019.00.740.

References

［1］KELLESARIAN S V，SUBHI ALHARTHI S，SALEH BINSHABAIB M，et al．Effect of local zoledronate delivery on osseointegration：a systematic review of preclinical studies［J］．Acta Odontol Scand，2017，75（7）：530-541．DOI：10.1080/00016357.2017.1350994.
［2］WEIDLE U H，BIRZELE F，KOLLMORGEN G，et al．Molecular mechanisms of bone metastasis［J］．Cancer Genomics Proteomics，2016，13（1）：1-12.
［3］吴家虹，刘惠君.骨转移瘤疼痛的诊断与治疗进展［J］．中国疼痛医学杂志，2007，13（2）：114-116．DOI：10.3969/j.issn.1006-9852.2007.02.017.
［4］陈丽，赵跃辉，刘小立.舒芬太尼在癌痛治疗中的应用进展［J］．中国疼痛医学杂志，2018，24（11）：859-862．DOI：10.3969/j.issn.1006-9852.2018.11.012.
［5］曹启旺，黄东，徐慧巧，等．普瑞巴林联合鞘内输注舒芬太尼治疗骨转移癌爆发痛的临床研究［J］．中南大学学报：医学版，2014，39（4）：384-388．DOI：10.11817/j.issn.1672-7347.2014.04.011.
CAO Q W，HUANG D，XU H Q，et al．Pregabalin combined with intrathecal sufentanil infusion for breakthrough pain in patients with bone metastases［J］．Journal of Central South University：Medical Science，2014，39（4）：384-388．DOI：10.11817/j.issn.1672-7347.2014.04.011.
［6］严鹏，晁腾飞，梅齐，等．盐酸羟考酮控释片联合氟比洛芬酯对中重度肿瘤骨转移疼痛患者的疗效观察［J］．华中科技大学学报：医学版，2016，45（5）：539-542．DOI：10.3870/j.issn.1672-0741.2016.05.013.
YAN P，CHAO T F，MEI Q，et al．Clinical efficacy of oxycodone hydrochloride controlled-release tablets combined with flurbiprofen axetil for moderate and severe cancer pain caused by bone metastasis［J］．Acta Medicinae Universitatis Scientiae et Technologiae Huazhong，2016，45（5）：539-542．DOI：10.3870/j.issn.1672-0741.2016.05.013.
［7］VAN ACKER H H，ANGUILLE S，WILLEMEN Y，et al．Bisphosphonates for cancer treatment：mechanisms of action and lessons from clinical trials［J］．Pharmacol Ther，2016，158：24-40．DOI：10.1016/j.pharmthera.2015.11.008.
［8］SINGH T，KAUR V，KUMAR M，et al．The critical role of bisphosphonates to target bone cancer metastasis：an overview［J］．J Drug Target，2015，23（1）：1-15．DOI：10.3109/1061186X.2014.950668.
［9］O'CARRIGAN B，WONG M H，WILLSON M L，et al．Bisphosphonates and other bone agents for breast cancer［J］．Cochrane Database Syst Rev，2017，10：CD003474．DOI：10.1002/14651858.CD003474.pub4.
［10］SAAD F，GLEASON D M，MURRAY R，et al．A randomized，placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma［J］．J Natl Cancer Inst，2002，94（19）：1458-1468．DOI：10.1093/jnci/94.19.1458.
［11］谢淑娟，占柳，潘卫红.唑来膦酸对颌骨骨质的影响及相关性研究进展［J］．华中科技大学学报：医学版，2012，41（1）：122-126．DOI：10.3870/j.issn.1672-0741.2012.01.030.
［12］罗琴琴，徐振晔，薛莎.骨痛灵方联合唑来膦酸治疗支气管肺癌骨转移伴中重度疼痛37例临床观察［J］．中医杂志，2018，59（21）：1853-1857．DOI：10.13288/j.11-2166/r.2018.21.013.
［13］GENG C J，LIANG Q，ZHONG J H，et al．Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma：a meta-analysis of randomised clinical trials［J］．BMJ Open，2015，5（6）：e007258．DOI：10.1136/bmjopen-2014-007258.
［14］李淼沅，袁润强，陈业辉.前列腺癌并骨转移的治疗新进展［J］．中华腔镜泌尿外科杂志：电子版，2018，12（2）：73-75.
LI M Y，YUAN R Q，CHEN Y H.New progress in the treatment of bone metastatic prostate cancer［J］．Chinese Journal of Endourology：Electronic Edition，2018，12（2）：73-75.
［15］何玉峰，陈进，鲁光平，等．来曲唑联合唑来膦酸治疗 ER/PR 阳性的绝经后乳腺癌骨转移疗效分析［J］．山东医药，2016，56（35）：65-67．DOI：10.3969/j.issn.1002-266X.2016.35.021.
［16］汤蕾.吉非替尼有效的非小细胞肺癌患者骨转移对其生存期的影响及骨转移患者的预后因素［D］．合肥：安徽医科大学，2014.
TANG L.Impact of bone metastasis on survival in non-small cell lung cancer with effective treatment of gefitinib and prognostic factors of patients with bone metastasis［D］．Hefei：Anhui Medical University，2014.
［17］黄宇，荆忍，潘灵辉.联合应用放射性核素89SrCl2与云克治疗肿瘤骨转移疗效［J］．实用医学杂志，2017，33（17）：2857-2860．DOI：10.3969/j.issn.1006-5725.2017.17.013.
HUANG Y，JING R，PAN L H.Efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone me-tastasis［J］．The Journal of Practical Medicine，2017，33（17）：2857-2860．DOI：10.3969/j.issn.1006-5725.2017.17.013.
［18］庞骁，周莉，牛书俐，等．氯化锶治疗前列腺癌骨转移病灶有效性和安全性的系统评价［J］．中国循证医学杂志，2017，17（11）：1305-1311.
PANG X，ZHOU L，NIU S L，et al．Efficacy and safety of strontium chloride for bone metastases from prostate cancer：a systematic review［J］．Chinese Journal of Evidence-Based Medicine，2017，17（11）：1305-1311.
［19］THAPA P，NIKAM D，DAS T，et al．Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases［J］．J Nucl Med，2015，56（10）：1513-1519．DOI：10.2967/jnumed.115.155762.
［20］SHARMA S，SINGH B，KOUL A，et al．Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases：patients' pain score analysis and personalized dosimetry［J］．Front Med（Lausanne），2017，4：46．DOI：10.3389/fmed.2017.00046.
［21］DE FELICE F，PICCIOLI A，MUSIO D，et al．The role of radiation therapy in bone metastases management［J］．Oncotarget，2017，8（15）：25691-25699．DOI：10.18632/oncotarget.14823.
［22］董新军.不同分割剂量调强适形放射治疗骨转移瘤临床研究［D］．济南：山东大学，2016.
DONG X J.The clinical study on different methods of fractionated dose of IMRT for the treatment of bone metastases［D］．Jinan：Shandong University，2016.
［23］秦晓玲，赵建国.调强放疗对恶性椎体转移瘤的镇痛疗效评价［J］．中国疼痛医学杂志，2018，24（3）：237-240．DOI：10.3969/j.issn.1006-9852.2018.03.017.
［24］吴宗明，唐献忠，杨庆诚.四肢骨转移癌126例手术疗效分析［J］．中国骨与关节杂志，2015，4（5）：343-347．DOI：10.3969/j.issn.2095-252X.2015.05.003.
［25］张福恒，陈德喜，郎继孝，等．聚甲基丙烯酸甲酯与磷酸钙骨水泥在骨质疏松性胸腰椎压缩骨折中的临床疗效分析［J］．中国骨与关节损伤杂志，2015，30（1）：21-23.
［26］叶勇，刘训伟，王志国，等．经皮骨成形联合多孔导管骨水泥灌注治疗转移性肿瘤所致长骨濒临骨折［J］．中国组织工程研究，2018，22（34）：5413-5418．DOI：10.3969/j.issn.2095-4344.0948.
［27］柯晋，张余，陈旭琼，等．影像引导下经皮微波消融治疗骨转移癌性疼痛［J］．中国骨科临床与基础研究杂志，2017，9（6）：365-369．DOI：10.3969/j.issn.1674-666X.2017.06.007.
KE J，ZHANG Y，CHEN X Q，et al．Image-guided percutaneous microwave ablation in the treatment of cancerous pain for patients with bone metastases［J］．Chinese Journal of Clinical and Basic Orthopaedic Research，2017，9（6）：365-369．DOI：10.3969/j.issn.1674-666X.2017.06.007.
［28］唐田，古善智，李国文，等．氩氦刀冷冻消融联合骨水泥治疗椎体转移瘤的效果［J］．广东医学，2015，36（18）：2868-2871．DOI：10.13820/j.cnki.gdyx.2015.18.037.
［29］许金.热疗联合健骨消痛方治疗骨转移癌疼痛30例临床观察［J］．北京中医药，2017，36（8）：744-746.
［30］汪德文，程明，郑亚君，等．放疗联合热疗治疗骨转移性肿瘤所致疼痛的疗效观察［J］．实用医学杂志，2013，29（3）：506-507．DOI：10.3969/j.issn.1006-5725.2013.03.068.
［31］周磊，冯利.益肾骨康方联合热疗辅助西药治疗骨转移癌疼痛患者90例临床研究［J］．中医杂志，2015，56（12）：1047-1050．DOI：10.13288/j.11-2166/r.2015.12.016.
［32］张坤尧，曹瑞治，陈晓东，等．125I粒子联合深部热疗在骨转移瘤治疗中的应用［J］．现代生物医学进展，2017，17（35）：6929-6933．DOI：10.13241/j.cnki.pmb.2017.35.030.
ZHANG K R，CAO R Z，CHEN X D，et al．The application of 125I particles combined with deep hyperthermia in the treatment of bone metastases［J］．Progress in Modern Biomedicine，2017，17（35）：6929-6933．DOI：10.13241/j.cnki.pmb.2017.35.030.
［33］CHI M S，YANG K L，CHANG Y C，et al．Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful bony metastases：a phase 3 prospective，randomized，controlled trial［J］．Int J Radiat Oncol Biol Phys，2018，100（1）：78-87．DOI：10.1016/j.ijrobp.2017.09.030.
［34］鲍晓玲.骨痛方外敷治疗局部骨转移疼痛的临床研究［D］．北京：北京中医药大学，2016.
［35］楚鑫，蒋运兰，廖天南，等．麝香散加味外敷对肾癌髋关节骨转移患者疼痛的影响研究［J］．四川中医，2018，36（10）：197-199.
CHU X，JIANG Y L，LIAO T N，et al．Effect of modified Shexiang powder external application on pain for patients with kidney cancer hip bone metastasis［J］．Journal of Sichuan Traditional Chinese Medicine，2018，36（10）：197-199.
［36］孟云.白马散外敷治疗骨转移中度癌痛的临床研究［D］．长沙：湖南中医药大学，2017.
［37］鲁叶云，徐振晔，王中奇，等．骨痛灵方联合西药治疗恶性肿瘤骨转移疼痛34例临床观察［J］．中医杂志，2015，56（5）：405-408．DOI：10.13288/j.11-2166/r.2015.05.013.
［38］杨柳.120例癌性疼痛相关因素分析及益肾骨康方治疗骨转移癌癌性疼痛临床疗效研究［D］．北京：北京中医药大学，2017.
［39］曹宏文，陈磊，冯懿赓，等．芪凌方联合中医针灸治疗前列腺癌骨转移的临床研究［J］．中国男科学杂志，2018，32（4）：40-45．DOI：10.3969/j.issn.1008-0848.2018.04.09.
［40］王敬，芦殿荣，毕然，等．耳穴埋豆干预骨转移中重度癌性疼痛临床观察30例［J］．云南中医中药杂志，2015，36（2）：43-45．DOI：10.16254/j.cnki.53-1120/r.2015.02.027.
［41］蒋云峰.穴位埋线疗法治疗骨转移性癌痛的临床研究［D］．广州：广州中医药大学，2014.
JIANG Y F.The clinical observation on the treatment of bone metastatic cancer pain is by catgut implantation［D］．Guangzhou：Guangzhou University of Chinese Medicine，2014.
［42］GDOWSKI A S，RANJAN A，VISHWANATHA J K.Current concepts in bone metastasis，contemporary therapeutic strategies and ongoing clinical trials［J］．J Exp Clin Cancer Res，2017，36（1）：108．DOI：10.1186/s13046-017-0578-1.

[1]	LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180.
[2]	WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124.
[3]	XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109.
[4]	ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186.
[5]	ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117.
[6]	SU Kaiqi, LYU Zhuan, WU Mingli, LUO Meng, GAO Jing, NIE Chenchen, LIU Hao, FENG Xiaodong. Effect of Electroacupuncture on BDNF/TrkB/PI3K/Akt Pathway and Hippocampal Neuronal Protection in Rats with Learning and Memory Impairment after Ischemia Reperfusion [J]. Chinese General Practice, 2023, 26(33): 4187-4193.
[7]	TU Jinkang, LI Fangfang, WU Xiaoqiong, XI Chong, QI Shaohua, CHEN Jun. Effectiveness of Backward Walking Based on Anti-gravity Treadmill Training System Combined with Conventional Low Back Core Training on Patients with Non-specific Low Back Pain [J]. Chinese General Practice, 2023, 26(33): 4203-4206.
[8]	LU Guangqi, ZHUANG Minghui, ZHU Liguo, GAO Jinghua, WEI Xu, LI Luguang, YU Jie. Interpretation of Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST) : Consensus Guidance from the American Society of Pain and Neuroscience (ASPN) in 2022 [J]. Chinese General Practice, 2023, 26(32): 3995-4000.
[9]	MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102.
[10]	WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962.
[11]	WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733.
[12]	ZHANG Ming, XU Jing, SUN Zhenhua, ZHAO Wenhao, MA Yingqian, ZHANG Jianqiao, SHEN Haiping. Improvement of Nutritional Status of Elderly Patients with Severe Obstruction Esophageal Carcinoma by Image-guided Photodynamic Therapy [J]. Chinese General Practice, 2023, 26(30): 3780-3784.
[13]	YUAN Xiwei, NAN Yuemin. Research Progress of Structure, Function and Mechanism of Action of Mitofusin 2 in Liver Diseases [J]. Chinese General Practice, 2023, 26(30): 3841-3846.
[14]	YAN Ke, WEI Wanyi, LI Shuguang, YAO Weinan, DONG Jing, WANG Xiaobin, ZHANG Xueyuan, YANG Jie, SHEN Wenbin, ZHU Shuchai. Effect of Consolidation Chemotherapy on Prognosis of StageⅡ-Ⅲ Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Concurrent Chemotherapy and Radio-therapy [J]. Chinese General Practice, 2023, 26(30): 3772-3779.
[15]	YAN Ke, WEI Wanyi, DENG Wenzhao, SHEN Wenbin, LI Shuguang, DU Xingyu, ZHANG Xueyuan, YANG Jie, ZHU Shuchai. Long-term Prognosis Analysis and Influencing Factors of Concurrent Chemotherapy and Radio-therapy for Cervical and Upper Thoracic Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(30): 3785-3790.